The Top Line

Since the first days of the new Trump administration, the White House has handed down orders to ban work focused on diversity, equity and inclusion (DEI) across the federal government. Some in the private sector—both inside and outside of healthcare—have followed the same path, eliminating DEI officer positions and ending initiatives that in some cases have been tied to millions of dollars in research funding. What does the field—and, ultimately, the patient—stand to lose from this effort? In this week’s episode of The Top Line, we hear from Nada Hanafi, co-founder of MedTech Color, a professional network aimed at building and supporting diverse leadership in the industry. Hanafi joins Fierce Medtech’s Conor Hale to discuss how studying diversity in a healthcare context has become integral to developing new medical breakthroughs and realizing the promise of precision medicine. To learn more about the topics in this episode: FDA issues draft guidance on ensuring pulse oximeter accuracy across skin tones  How Trump's DEI executive orders could impact healthcare  After White House transition, FDA’s diversity guidance for clinical trials no longer available  As Trump targets DEI practices, 4 pharmas reaffirm commitment to diversifying clinical trials  Amid Trump's push to abolish DEI, Roche and Novartis adjust hiring initiatives: reports  See omnystudio.com/listener for privacy information.

In this episode of The Top Line, sponsored by PatientPoint, Andrew Schultz, President of PatientPoint Precision, discusses how hypertargeting and contextual relevance are redefining patient marketing. Traditional direct-to-consumer (DTC) campaigns often rely on educated guesses, but PatientPoint Precision blends EHR data and patient context to deliver hyper-personalized, high-impact messages. By engaging patients at critical touchpoints—like logging into a portal or checking in for an appointment—marketers can deliver tailored, valuable content that enhances patient experiences and drives better health outcomes. Schultz emphasizes the importance of trust, consent, and privacy in utilizing this treasure trove of data securely. With PatientPoint Precision’s ability to integrate data and context, brands can now create robust, personalized campaigns that truly resonate with their target audiences. Listen to the full episode to learn how this new DTC approach is transforming patient engagement.See omnystudio.com/listener for privacy information.

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new biosimilars or generics in 2025, as featured in the latest edition of Fierce Pharma’s annual special report documenting the 10 biggest losses of U.S. exclusivity expected throughout the year. In this week’s episode of The Top Line, we dig into the report, which details the stories behind 10 key medicines that are set to face off against new generic or biosimilar competitors this year as their patents expire. Fierce’s Eric Sagonowsky and Angus Liu recap the report, sharing their perspectives on several of the drugs and discussing the industry effects of 2025’s sizable patent cliff. To learn more about the topics in this episode: The top 10 drugs losing US exclusivity in 2025  After patent settlement, Amgen scores FDA nod for its biosimilar version of J&J's Stelara  Amgen grabs FDA thumbs-up for Soliris biosim, eyes 2025 launch  Novartis wins 11th-hour bid to block generic version of blockbuster heart med Entresto  Amgen settles Prolia patent suit with Celltrion, teeing up potential biosimilar launch in June  See omnystudio.com/listener for privacy information.

Agenus Chief Medical Officer Dr. Steven O'Day joined Fierce's Chris Hayden on a recent sponsored episode of The Top Line podcast to discuss the evolving landscape of cancer immunotherapy. O'Day, a medical oncologist with 30 years of experience, explained the fundamental differences between immunotherapy and traditional cancer treatments like chemotherapy, surgery, and radiation. He emphasized immunotherapy's potential for durable responses and even cures by activating the body's own T-cells to fight cancer. The conversation addressed the challenges of treating "cold" tumors, such as colorectal cancer, which are less visible to the immune system. O'Day highlighted Agenus's pipeline of antibodies, botensilimab (BOT) and balstilimab (BAL), designed to trigger T-cell recognition of these colder cancers. O'Day expressed his excitement about a potential "2.0 revolution" of immuno-oncology, expanding the benefits of immunotherapy to a wider range of cancers. He described BOT and BAL as a "one-two punch," with BOT priming T-cells and BAL preventing their exhaustion. Listen to the full conversation on the latest episode of The Top Line.See omnystudio.com/listener for privacy information.

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global pharma companies record sales declines. But that growth may be short-lived, as many of those same companies forecast more muted revenue increases in 2025. In this week’s episode of The Top Line, we dissect the unprecedented revenue growth enjoyed by many of the world’s top pharma companies by sales in the fourth quarter of last year. Fierce Pharma’s Kevin Dunleavy and Fraiser Kansteiner discuss the period’s results, examine the companies’ performance expectations going into 2025 and consider whether the momentum seen in Q4 is repeatable or more of an anomaly. To learn more about the topics in this episode: Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4 Eli Lilly logs massive Q4 revenue jump—but it's not just thanks to Mounjaro and Zepbound Pfizer harnesses COVID fluctuations to clinch Q4 gains as RSV vaccine sales plummet Astellas takes $760M charge, reveals slowdown for eye drug Izervay after regulatory stumbles This episode is brought to you by Cencora.See omnystudio.com/listener for privacy information.

In the latest episode of The Top Line, Chris Hayden of Fierce Pharma sits down with Mary Lou Glotzbach, senior manager of drug delivery partnerships at Grand River Aseptic Manufacturing (GRAM). They explore the evolving landscape of biologics, the increasing importance of cold chain management, and how contract development and manufacturing organizations (CDMOs) are adapting to industry shifts. Glotzbach highlights a growing trend in biotech: transitioning patient treatments from infusion centers to home delivery. This shift demands innovative drug delivery solutions, including wearable devices and auto-injectors, capable of handling high-viscosity biologics. She also emphasizes the industry's push for smaller batch sizes due to the high cost and complexity of producing biologics, which challenges traditional manufacturing processes. Another key discussion point is the rising demand for transparency and early collaboration between pharmaceutical companies, CDMOs, and device manufacturers. Glotzbach notes that CDMOs are now being brought into the development process earlier than ever, allowing for better alignment on formulation, container design, and regulatory compliance. The conversation also touches on Annex 1 compliance and the need for standardization in primary containers like syringes and cartridges. Glotzbach envisions a future where standardized components streamline production, making drug development more efficient. For anyone interested in the intersection of biologics, manufacturing, and drug delivery innovation, this episode offers valuable insights into how GRAM is helping shape the future of the industry. Tune in to learn more about the latest advancements and challenges in aseptic manufacturing.See omnystudio.com/listener for privacy information.

Dr. Luis Buzón, an infectious disease specialist and spokesman for the Spanish Society of Infectious Diseases, sheds light on the vital role of real-world evidence in HIV care. He emphasizes how long-term data reveal treatment effectiveness and side effects often missed in clinical trials. Buzón shares a personal connection to HIV advocacy, inspired by his father's pioneering work in Spain. The discussion highlights the importance of inclusive research to improve health outcomes and the ongoing journey towards compassionate, evidence-based care.

The biotech sector is buzzing with excitement over massive fundraising achievements in 2024. Xaira Therapeutics made headlines by securing a staggering $1 billion, reshaping industry norms. The conversation unfolds around key players like Treeline Biosciences, Kylara Therapeutics, and Mirador Therapeutics, each raising impressive sums. Innovations in precision medicine and obesity treatments are spotlighted, revealing how these trends are driving investment strategies and shifting the biotech landscape. It's a thrilling time for biotech as money pours in!

Recent research shifts the understanding of Huntington's disease from toxic protein buildup to a 'ticking DNA clock' that causes rapid neuron death. Innovative technologies like Droplet Single Cell Genomics reveal cell-specific toxicity, providing insights into the disease's fatal effects on brain neurons. The importance of human brain tissue analysis uncovers mechanisms behind selective cell death. New therapies focusing on genetic aspects may pave the way for effective treatments, drawing inspiration from genetics of resilient individuals.

James Waldron, a journalist from Fierce Biotech, brings insights on the biggest clinical trial failures of 2024. He highlights the disappointing results from major companies like AbbVie and Pfizer, particularly in trials for schizophrenia and Duchenne muscular dystrophy. The discussion delves into lessons learned from these setbacks and the human impact of failed trials. Waldron and Gabrielle Masson also explore the ongoing challenges the industry faces and the crucial need for innovative treatments to improve patient outcomes.